Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Rosenblatt

Urogynecology and Reconstructive Pelvic Surgery Cambridge, MA Medical Doctor

NPI 1629048665 CMS profile 300029

725 Concord Ave, Ste 3300, Cambridge, MA 02138

Open in the dashboard

General payments

$222,587

595 records reported · program years 2019–2025

Research payments

$8,975

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,369 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Peter Rosenblatt of Cambridge, MA is reported in the CMS Open Payments database as having received $222,587 across 595 general payments and $8,975 in research payments paid to them. Separately, studies naming them as principal investigator received $14,369 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,571 31
2024 General $12,278 68
2023 General $26,502 87
2022 General $28,104 121
2022 Research $6,104 1
2021 General $39,907 90
2021 Research $1,111 1
2020 General $31,688 51
2020 Research $1,760 4
2019 General $81,537 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Rosenblatt
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Peter Rosenblatt were reported at $2,571. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Peter Rosenblatt Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $81,537 $358 $132–$1,270 $163
2020 $31,688 $198 $86–$642 $114
2021 $39,907 $361 $118–$1,182 $132
2022 $28,104 $410 $128–$1,175 $149
2023 $26,502 $434 $152–$1,344 $160
2024 $12,278 $494 $193–$1,331 $164
2025 $2,571 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $85,591 130 payments
  2. Coloplast Corp $42,739 85 payments
  3. Medtronic USA, Inc. $27,718 38 payments
  4. Davol Inc. $18,333 4 payments
  5. Medtronic, Inc. $17,304 56 payments
  6. CooperSurgical, Inc. $12,682 8 payments
  7. Hologic, LLC $4,596 19 payments
  8. Stryker Corporation $3,500 3 payments
  9. Axonics Modulation Technologies, Inc. $2,147 30 payments
  10. AbbVie, Inc. $1,488 46 payments
  11. Other $6,490 176 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,350 36 payments
  2. Consulting Fee $49,477 37 payments
  3. Education $31,786 31 payments
  4. Food and Beverage $19,736 435 payments
  5. Acquisitions $18,333 4 payments
  6. Travel and Lodging $15,725 49 payments
  7. Gift $180 3 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $27,718 38 payments
  2. CROSSBOSS $21,391 9 payments
  3. Solyx SIS System $18,501 25 payments
  4. INTERSTIM Sacral Nerve Stimulation $16,693 51 payments
  5. ALTIS Female Incontinence $16,675 32 payments
  6. Altis Women's Health $14,367 37 payments
  7. RESTORELLE $9,730 2 payments
  8. GENERAL - PELVIC ORGAN PROLAPSE $6,714 4 payments
  9. GENERAL THERAPIES $6,584 16 payments
  10. Advantage System $6,302 17 payments
  11. Other $49,665 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $7,750 3 payments
  2. FEMSelect Inc. $1,225 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

607

Median for Obstetrics & Gynecology: 65

Drug cost

$211,629

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

58.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 116 $102,861
Myrbetriq Mirabegron Brand 87 $55,976
Estradiol Generic 179 $18,911
Premarin Estrogens, Conjugated Brand 31 $13,466
Mirabegron Er Mirabegron Brand 17 $7,455
Estring Estradiol Brand 11 $5,668
Yuvafem Estradiol Brand 26 $4,620
Methenamine Hippurate Generic 39 $2,092
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 51 $277
Trimethoprim Generic 18 $189

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$162,950

Of which drugs: $16,284

Medicare patients

348

Average age 75

Services billed

4,699

348 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 53%
Osteoporosis 32%
Depression 25%
Ischemic heart disease 16%
Diabetes 14%
Cancer 14%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 22 3,302 $16,284

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $400
$400 — 3,302
GEMTESA
  • Sumitomo Pharma America, Inc. $215
$215 116 —
Veozah
  • Astellas Pharma US Inc $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

601 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record